We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
The Best dot dot is a positive review website that lets individuals celebrate the good things in life and in turn, enables others to benefit from those experiences. The company aims to create a leading platform, with a large, engaged user base and ultimately to maximise shareholder value. The company has a full robust technology infrastructure and platform in place, consisting of a mix of unique in house technology and tried and tested industry-standard platforms. Significant work has already been done to create the IP that will be purchased by the company and the funds raised will be used to build on the work already done and to take the business to the next level. By increasing the user base, the revenue will rapidly increase as the company introduces additional revenue streams.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £19,050
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Invluencer is a Venture Capital (VC) company with an economic model designed to bring VC to the masses. Invluencer believes in boosting greater investment capability between investors and company representatives. This is undertaken by creating a smart-contract enabled 'Intelligent Wallet' for autonomous investment in vetted high-growth companies facilitated by Invluencer’s unique Multi-Asset Platform (I-MAP) and Intelligent Distributed Due Diligence (i3D) platform. Through these platforms, the company aims to simplify investment and open liquidity between worthy companies and accredited investors. The company will use the investments to continue the development of due diligence and fund management platforms, strengthen the investment team and analysis team, strengthen relationships and partnerships within the VC ecosystem.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £154,000
Elute Intelligence is an online platform that makes searching documents fast, simple, and accurate. The platform is optimised to handle a variety of tasks such as plagiarism detection, patent searching, fraud detection, governance and compliance, and e-discovery to name a few. Using a unique AI-based system, users can upload long-form documentation, and the system will analyse, tag, and find related articles across a wide range of academic journals and data sources. The company is looking to engage in partnerships: with government and commercial R&D teams to help accelerate research into Covid-19, with development partners to help expand the system into other research areas, and with investors interested in an AI and big data platform that can transform scientific research processes.

Pitch Rated

40%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Themis is a regulatory technology company that helps organisations mitigate the risk and impact of all forms of financial crime such as money laundering, bribery, corruption, cybercrime, theft, slavery/human trafficking, and fraud. The platform is designed to provide insights and intelligence on the latest threats, trends, and criminal techniques whilst helping clients complete due diligence on their clients, staff, and supply chains. Themis works alongside the Themis Charitable Trust to ensure the reduction of financial crime. The company also supports the UN Global Compact taking into account the fundamental responsibilities of business in the areas of human rights, labour, environment, and anti-corruption. Themis will use the investment to grow its business across different verticals.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,300,000
Buyerdock is a Software as a Service (SAAS) global discovery platform that allows retail buyers instant access to compliant ready brands through the company's intelligent cloud technology. Buyerdock enables each supplier to upload details like product information, barcodes, images, and pack size on the portal. Retail buyers can then scrutinise all the available information within specific product categories and select the inventory they wish to purchase intuitively. Buyerdock received a mention from the former CEO of Sainsbury's that the former will speed up the buying process from 6 months to under 3 for retail buyers. The company is in talks with the top six UK retailers, such as Tesco, Marks & Spencer, Home Retail Group, Sainsbury's, Asda, and Morrisons. It will use the investment to grow its business and target the approximate 306,000 retail outlets in the UK, of which around 200,000 are independent retailers.

Pitch Rated

36%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £121,157
Screach provides consumer focused venues with the ability to intelligently engage and interact with their customers via installed digital displays (TVs) and mobile phones. The Screen Reach software dynamically changes the screen content to improve its effectiveness in driving more sales by displaying relevant engaging content and promotions. 
days to go: Expired investment: £590,000
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph